Global Acoustic Neuroma Market Size, Forecast, and Trend Highlights Over 2025-2037
Acoustic Neuroma Market size was valued at USD 1.7 billion in 2024 and is likely to cross USD 4 billion by 2037, registering more than 7.6% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of acoustic neuroma is estimated at USD 1.8 billion.
The global market is witnessing steady growth, driven by increasing awareness, improved diagnostic capabilities, and the rising preference for minimally invasive treatment options. Technological advancements in imaging and radiosurgery have enhanced early detection and treatment precision, leading to better patient outcomes. According to the U.S. Census Bureau Population Projections for 2020 to 2060, the number of people aged 85 years and older is projected to double from 6.5 million to 11.8 million by 2035. This is further expected to triple by 2060, to 19 million people. The growing geriatric population, which is more prone to develop vestibular conditions, is driving the demand across both developed and developing regions.
The market is also benefiting from a shift toward outpatient and non-surgical procedures, particularly in developed regions. Furthermore, clinical trials and drug approvals are attracting several new investors to the market. The rise of specialized cross-border medical tourism in countries such as India is also contributing to market expansion. However, disparities in access to specialized care and high treatment costs in some regions continue to pose challenges. Emerging trends such as the integration of telehealth for pre- and post-treatment consultations and the expansion of outpatient care models have boosted the global market significantly.
Acoustic Neuroma Sector: Growth Drivers and Challenges
Growth Drivers
- Advancements in non-invasive treatments: The emergence and refinement of stereotactic radiosurgery techniques, such as GammaKnife and CyberKnife have significantly transformed the market landscape. In June 2024, Fortis Memorial Research Institute launched South Asia's First Gamma Knife Esprit, a groundbreaking version of the Leksell Gamma Knife, for non-surgical high-precision treatment. Further ongoing innovations in radiotherapy planning and imaging integration are enhancing outcomes and boosting adoption.
- Increasing healthcare expenditure: Global growth in healthcare budgets, particularly across developed economies, is translating into improved infrastructure, more trained specialists, and wider availability of sophisticated treatment technologies. In February 2025, a KFF analysis revealed that the federal government spent USD 1.9 trillion on programs and services related to health care in FY 2024. Simultaneously, awareness campaigns and medical education are equipping physicians and patients with better knowledge about the symptoms and risks of acoustic neuromas.
Challenge
- Limited access to specialized care: In low- and middle-income countries, a shortage of trained neurosurgeons, audiologists, and specialized centers poses a major barrier to effective treatment. Patients in rural or underserved areas face long travel distances, high out-of-pocket costs, and delayed diagnosis due to a lack of awareness of infrastructure. This inequality in access often results in advanced-stage presentation, reduced treatment options, and poorer outcomes, limiting the global expansion of the acoustic neuroma treatment market.
Acoustic Neuroma Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.6% |
|
Base Year Market Size (2024) |
USD 1.7 billion |
|
Forecast Year Market Size (2037) |
USD 4 billion |
|
Regional Scope |
|
Acoustic Neuroma Segmentation
Treatment (Pharmacological intervention, Surgical intervention, Radiation therapy)
Radiation therapy segment in acoustic neuroma market is anticipated to register a considerable share during the forecast period owing to its non-invasive nature, precision, and effectiveness in treating tumors without the need for open surgery. The growing geriatric population, which often presents with comorbidities that make surgery risky, is further driving the demand for radiation-based treatment options. The rising body of clinical evidence supporting long-term tumor control with radiosurgery has also contributed to its dominance in this segment.
End user (Hospitals, Diagnostic Centers, Academic and Research Institutes)
Diagnostic centers are anticipated to register a considerable share during the forecast period. The increasing awareness of symptoms such as hearing loss and balance issues has prompted more individuals to seek diagnostic evaluations, often starting at specialized imaging centers. Moreover, the rising trend of outsourcing diagnostic services by hospitals and clinics to third-party centers, due to cost-efficiency and access to specialized expertise, has further strengthened the position of diagnostic centers. Integration of AI-driven imaging analysis and real-time reporting systems also enhances their operational efficiency, attracting both patients and healthcare professionals for initial assessments.
Our in-depth analysis of the global acoustic neuroma market includes the following segments:
|
Types |
|
|
Treatment |
|
|
End user |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAcoustic Neuroma Industry - Regional Synopsis
North America Market Analysis
North America acoustic neuroma market is anticipated to register significant growth, driven by advanced healthcare infrastructure, high awareness levels, and strong reimbursement frameworks. The region benefits from early adoption of innovative diagnostic and therapeutic technologies, including AI-integrated MRI systems and precision radiosurgery. Increasing incidence of age-related hearing disorders and proactive health screening practices are also supporting market expansion across both urban and semi-urban areas. Collaborations between research institutions and healthcare providers continue to fuel clinical innovation and improve patient outcomes.
The U.S. market holds a major share in the region owing to its large patient population, robust specialist network, and widespread access to cutting-edge treatment facilities. The presence of leading academic medical centers and ongoing clinical trials further enhances the country’s leadership in advancing acoustic neuroma care. In November 2024, Sangamo Therapeutics, Inc. received clearance from the U.S. Food and Drug Administration for the investigational new drug (IND) application for its ST-503 program for the treatment of intractable pain due to iSFN.
APAC Market Statistics
APAC market is expected to witness the fastest growth. Driven by improving healthcare infrastructure, increasing awareness about neurological disorders, and a rising aging population. Rising healthcare expenditure and ongoing digital health transformation are expected to further accelerate growth in the coming years. Countries such as China, Japan, and South Korea are investing in advanced diagnostic imaging technologies and expanding access to radiosurgery techniques.
India market is gradually growing, with private hospitals playing a key role in introducing advanced treatment options, and medical tourism is boosting demand from neighboring countries. For instance, in March 2025, Ion Beam Applications S.A. signed a term sheet with Apollo Hospitals Enterprise Limited to supply one Proteus ONE compact proton therapy solution, plus a second one as an option. This enables Apollo to expand access to proton therapy in India.
Companies Dominating the Acoustic Neuroma Landscape
- GE Healthcare
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Siemens Healthcare
- Philips Healthcare
- Shimadzu Corporation
- Toshiba Medical Systems Corporation
- F. Hoffmann-La Roche Ag
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Electa
Companies operating in the acoustic neuroma market are adopting strategic collaborations, partnerships with hospitals, diagnostic chains, and academic institutions, to help drive research, streamline clinical workflows, and expand access to specialized care. Additionally, companies are focusing on entering emerging markets through local partnerships and training programs to address gaps in the skilled workforce and infrastructure. Some of these companies are mentioned below:
Recent Developments
- In July 2024, SamanTree Medical announced the closing of USD 14 million as part of a Series B financing round, to further develop and commercialize the Histolog Scanner, expand its reach in Europe and the United States, and enhance its digital suite.
- In June 2024, Amethyst Radiotherapy Group secured a USD 339.5 million financing agreement with Credit funds managed by Ares Management Corporation to advance cancer treatment across Europe.
Author Credits: Radhika Pawar
- Report ID: 898
- Published Date: Jun 06, 2025
- Report Format: PDF, PPT
